XML 42 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Segment Information (Tables)

6 Months Ended

Jun. 30, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

Segment information for the three and six months ended June 30, 2024 and 2023 is as follows (in thousands):

		Three Months Ended June 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	25,225			$	—			$	—			$	25,225
Cost of revenues			770				—				—				770
Gross profit			24,455				—				—				24,455
Operating expenses excluding cost of revenues:
Selling and marketing			14,414				—				—				14,414
Research and development			3,077				278				—				3,355
General and administrative			2,549				874				1				3,424
Total operating expenses excluding cost of revenues			20,040				1,152				1				21,193
Income (loss) from operations		$	4,415			$	(1,152	)		$	(1	)		$	3,262
Supplemental disclosure of stock-based compensation expense:
General and administrative		$	—			$	16			$	—			$	16
Stock-based compensation total		$	—			$	16			$	—			$	16

		Six Months Ended June 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	52,397			$	—			$	—			$	52,397
Cost of revenues			1,749				—				—				1,749
Gross profit			50,648				—				—				50,648
Operating expenses excluding cost of revenues:
Selling and marketing			26,956				—				—				26,956
Research and development			5,086				451				—				5,537
General and administrative			4,806				2,015				1				6,822
Total operating expenses excluding cost of revenues			36,848				2,466				1				39,315
Income (loss) from operations		$	13,800			$	(2,466	)		$	(1	)		$	11,333
Supplemental disclosure of stock-based compensation expense:
General and administrative		$	—			$	27			$	—			$	27
Stock-based compensation total		$	—			$	27			$	—			$	27

		Three Months Ended June 30, 2023
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	29,329			$	—			$	—			$	29,329
Cost of revenues			1,077				—				—				1,077
Gross profit			28,252				—				—				28,252
Operating expenses excluding cost of revenues:
Selling and marketing			17,999				—				—				17,999
Research and development			3,568				—				—				3,568
General and administrative			1,174				—				537				1,711
Total operating expenses excluding cost of revenues			22,741				—				537				23,278
Income (loss) from operations		$	5,511			$	—			$	(537	)		$	4,974
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation total		$	—			$	—			$	—			$	—

		Six Months Ended June 30, 2023
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	54,260			$	—			$	—			$	54,260
Cost of revenues			2,202				—				—				2,202
Gross profit			52,058				—				—				52,058
Operating expenses excluding cost of revenues:
Selling and marketing			30,767				—				—				30,767
Research and development			6,203				—				—				6,203
General and administrative			2,896				—				554				3,450
Total operating expenses excluding cost of revenues			39,866				—				554				40,420
Income (loss) from operations		$	12,192			$	—			$	(554	)		$	11,638
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation total		$	—			$	—			$	—			$	—

The table below presents total assets as of June 30, 2024 and December 31, 2023.

		June 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Total assets		$	109,484			$	10,533			$	912			$	120,929

		December 31, 2023
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Total assets		$	101,761			$	13,865			$	913			$	116,539

The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.

		Six Months Ended June 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Purchase of property and equipment		$	1,673			$	14			$	—			$	1,687

		Six Months Ended June 30, 2023
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Purchase of property and equipment		$	4,219			$	—			$	—			$	4,219

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration